세계의 항독소 시장 규모, 점유율, 성장 분석 : 항독소 유형별, 생물 유형별, 작용기전별, 최종사용자별, 지역별 - 산업 예측(2025-2032년)
Anti-Venom Market Size, Share, and Growth Analysis, By Anti-venom Type (Polyvalent, Monovalent), By Species Type (Snake Antivenom, Scorpion Anti-venom), By Mode of Action, By End User, By Region - Industry Forecast 2025-2032
상품코드:1647527
리서치사:SkyQuest Technology Consulting Pvt. Ltd.
발행일:2025년 01월
페이지 정보:영문 157 Pages
라이선스 & 가격 (부가세 별도)
한글목차
항독소 시장 규모는 2023년 21억 달러로 평가되었습니다. 또한, 예측 기간(2025-2032년) 동안 8.1%의 연평균 복합 성장률(CAGR)로 2024년 22억 7,000만 달러에서 2032년에는 42억 3,000만 달러로 성장할 것으로 예상됩니다.
세계 항독소 시장은 뱀에 물리는 비율이 증가하고 효과적인 치료 옵션에 대한 인식이 높아짐에 따라 크게 성장하고 있습니다. 세계보건기구(WHO)에 따르면, 뱀에 물린 사고는 매년 수만 명이 사망하고 생존자 중 상당수가 장기적인 장애를 겪고 있으며, 특히 사하라 사막 이남 아프리카, 남아시아, 동남아시아 등 독이 있는 종에 감염된 지역에서는 공중보건에 큰 문제가 되고 있습니다. 정부, NGO 및 의료 서비스 제공업체는 항독소에 대한 접근성을 적극적으로 개선하고 생산 및 유통을 촉진하기 위해 노력하고 있습니다. 생명공학의 발전으로 더 안전하고 효과적인 제제가 개발되어 치료 결과가 개선되고 있습니다. 그러나 높은 비용, 표준화 부족, 복잡한 제조 공정 등의 문제가 시장 확대에 걸림돌로 작용하고 있으며, 특히 경제적인 여유가 중요한 문제인 저소득 지역 시장 확대에 걸림돌로 작용하고 있습니다.
South African Vaccine Producers(Pty) Ltd(South Africa)
Instituto Butantan(Brazil)
Instituto Clodomiro Picado(Costa Rica)
Vins Bioproducts Limited(India)
MicroPharm Limited(United Kingdom)
Protherics PLC(United Kingdom)
Inosan Biopharma(Spain)
Sanofi Pasteur(France)
Serum Institute of India Pvt. Ltd.(India)
Bio-Pharmaceutical Corporation Ltd.(China)
Thai Red Cross Society(Thailand)
결론과 추천 사항
LSH
영문 목차
영문목차
Anti-Venom Market size was valued at USD 2.1 billion in 2023 and is poised to grow from USD 2.27 billion in 2024 to USD 4.23 billion by 2032, growing at a CAGR of 8.1% during the forecast period (2025-2032).
The global anti-venom market is experiencing significant growth, driven by the rising incidence of snakebites and increasing awareness of effective treatment options. Snakebites remain a major public health concern, particularly in regions such as Sub-Saharan Africa, South Asia, and Southeast Asia, where venomous species are prevalent. According to WHO, snakebites cause tens of thousands of deaths annually, with many survivors suffering long-term disabilities. Governments, NGOs, and healthcare providers are actively improving access to anti-venom, boosting production and distribution. Advancements in biotechnology have led to safer and more effective formulations, enhancing treatment outcomes. However, challenges such as high costs, lack of standardization, and complex production processes continue to hinder market expansion, particularly in low-income regions where affordability remains a critical issue.
Top-down and bottom-up approaches were used to estimate and validate the size of the Anti-Venom Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Anti-Venom Market Segments Analysis
Global Anti-Venom Market is segmented by Anti-venom Type, Species Type, Mode of Action, End User and region. Based on Anti-venom Type, the market is segmented into Polyvalent, Monovalent and Others. Based on Species Type, the market is segmented into Snake Antivenom, Scorpion Anti-venom, Spider Anti-venom and Others. Based on Mode of Action, the market is segmented into Cytotoxic, Neurotoxic, Haemotoxic, Cardiotoxic, Myotoxic and Others. Based on End User, the market is segmented into Hospitals & clinics, Ambulatory Surgical Centers, Research Institutes and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Anti-Venom Market
Our analysis reveals that the growing incidence of snakebite cases globally is a crucial factor driving the expansion of the anti-venom market. Snakebites pose a severe public health challenge, particularly in regions with dense snake populations, such as parts of Asia, Africa, and Latin America. The World Health Organization (WHO) classifies snakebite envenomation as a neglected tropical disease, emphasizing the urgent need for effective treatments. Rising awareness, improved healthcare access, and government initiatives to provide life-saving anti-venom therapies are further propelling market growth. As snakebite cases continue to surge, the demand for reliable and affordable anti-venom solutions is expected to rise.
Restraints in the Anti-Venom Market
Our analysis reveals that inadequate healthcare infrastructure and logistical challenges in remote or rural areas significantly restrain the growth of the global anti-venom market. Limited access to medical facilities and a lack of proper cold chain storage for anti-venom distribution hinder its timely availability, increasing the risk of fatality and severe complications among snakebite victims. Additionally, transportation difficulties and insufficient trained healthcare personnel further exacerbate the issue, delaying critical treatment. These barriers contribute to uneven market penetration, limiting the adoption of anti-venom therapies in regions where snakebites are prevalent, ultimately affecting the overall market growth and accessibility of life-saving treatments.
Market Trends of the Anti-Venom Market
Our analysis reveals that increasing awareness and education campaigns are emerging as a key trend in the Global Anti-Venom Market. Governments, healthcare organizations, and non-profits are actively launching initiatives to educate healthcare professionals, communities, and individuals about snakebite prevention, early recognition, and appropriate treatment. These programs aim to reduce mortality and morbidity associated with venomous bites by improving response times and access to medical intervention. Additionally, digital platforms, workshops, and community outreach efforts are enhancing public knowledge and preparedness, ultimately driving demand for anti-venom products and supporting the market's growth through improved treatment accessibility and effectiveness.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technological Advancement
Trade Analysis
Global Anti-Venom Market Size by Anti-venom Type & CAGR (2025-2032)
Market Overview
Polyvalent
Monovalent
Others
Global Anti-Venom Market Size by Species Type & CAGR (2025-2032)
Market Overview
Snake Antivenom
Scorpion Anti-venom
Spider Anti-venom
Others
Global Anti-Venom Market Size by Mode of Action & CAGR (2025-2032)
Market Overview
Cytotoxic
Neurotoxic
Haemotoxic
Cardiotoxic
Myotoxic
Others
Global Anti-Venom Market Size by End User & CAGR (2025-2032)
Market Overview
Hospitals & clinics
Ambulatory Surgical Centers
Research Institutes
Others
Global Anti-Venom Market Size & CAGR (2025-2032)
North America (Anti-venom Type, Species Type, Mode of Action, End User)
US
Canada
Europe (Anti-venom Type, Species Type, Mode of Action, End User)
Germany
Spain
France
UK
Italy
Rest of Europe
Asia Pacific (Anti-venom Type, Species Type, Mode of Action, End User)
China
India
Japan
South Korea
Rest of Asia-Pacific
Latin America (Anti-venom Type, Species Type, Mode of Action, End User)
Brazil
Rest of Latin America
Middle East & Africa (Anti-venom Type, Species Type, Mode of Action, End User)
